The UK and US have established a landmark bilateral deal that will ensure zero duties on British medicine exports being sold in the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the public health system. This pledge secures that import taxes on these crucial goods will remain at zero for a timeframe of three years.
This deal is in response to recent threats to dramatically increase tariffs on branded drug imports, with figures mentioned up to double the cost.
"This deal between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and introduces much-needed fairness to American-British pharmaceutical trade," an announcement noted.
Commercial Significance
Pharmaceuticals constitute one of the the United Kingdom's largest exports to the United States, which is clearly the largest buyer for major British pharmaceutical firms.
Trade data reveal that in the one-year period to the end of September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This figure represented nearly one-fifth of British export trade in that span.
"This deal secures employment, stimulates funding and facilitates the UK to establish itself as a international leader for medical research," a government official stated.
Detailed British Pledges
The deal includes several specific changes from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall public funding on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at 15%. Previously, rebates topped 20%.
Recent Tensions
This agreement follows a ongoing tension between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were exacerbated by claims that US customers were paying significantly more for the same drugs than patients in the other developed nations.
In recent months, several major drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
One official acknowledged that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a proportion of its total funding over the previous ten-year period.
